VCM
DFTX

Versant Capital Management’s Definium Therapeutics DFTX Stock Holding History

Versant Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.23K Buy
+90
New +$2.22K ﹤0.01% 2455
2025
Q2 		– Sell
-1,137
Closed -$6.65K – 2696
2025
Q1 		$6.65K Buy
+1,137
New +$8.14K ﹤0.01% 1915

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Versant Capital Management's DFTX Position: Q2 2026 in Review

Versant Capital Management opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 90 shares worth $4.23K. The stake represents ﹤0.01% of the portfolio and ranks #2455 among its holdings. This is a return to the name: Versant Capital Management previously reported a position in DFTX as recently as Q1 2025.

Versant Capital Management first reported a position in DFTX in Q1 2025 and has held it in 2 quarters since. The position peaked at $6.65K in Q1 2025. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Versant Capital Management held 90 shares of Definium Therapeutics worth $4.23K as of Q2 2026.
  • Definium Therapeutics was a new Versant Capital Management position in Q2 2026.
  • Definium Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2455 holding.
  • Versant Capital Management first reported a position in Definium Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • Versant Capital Management's Definium Therapeutics position peaked at $6.65K in Q1 2025.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.